418 related articles for article (PubMed ID: 37510269)
1. Biomarkers in Breast Cancer: An Old Story with a New End.
Neves Rebello Alves L; Dummer Meira D; Poppe Merigueti L; Correia Casotti M; do Prado Ventorim D; Ferreira Figueiredo Almeida J; Pereira de Sousa V; Cindra Sant'Ana M; Gonçalves Coutinho da Cruz R; Santos Louro L; Mendonça Santana G; Erik Santos Louro T; Evangelista Salazar R; Ribeiro Campos da Silva D; Stefani Siqueira Zetum A; Silva Dos Reis Trabach R; Imbroisi Valle Errera F; de Paula F; de Vargas Wolfgramm Dos Santos E; Fagundes de Carvalho E; Drumond Louro I
Genes (Basel); 2023 Jun; 14(7):. PubMed ID: 37510269
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of gene-expression signatures in early stage breast cancer.
Kwa M; Makris A; Esteva FJ
Nat Rev Clin Oncol; 2017 Oct; 14(10):595-610. PubMed ID: 28561071
[TBL] [Abstract][Full Text] [Related]
3. Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine.
Kamel HFM; Al-Amodi HSAB
Genomics Proteomics Bioinformatics; 2017 Aug; 15(4):220-235. PubMed ID: 28813639
[TBL] [Abstract][Full Text] [Related]
4. Current advances in the diagnosis and personalized treatment of breast cancer: lessons from tumor biology.
Kern R; Correa SC; Scandolara TB; Carla da Silva J; Pires BR; Panis C
Per Med; 2020 Sep; 17(5):399-420. PubMed ID: 32804054
[TBL] [Abstract][Full Text] [Related]
5. Decoding the usefulness of non-coding RNAs as breast cancer markers.
Amorim M; Salta S; Henrique R; Jerónimo C
J Transl Med; 2016 Sep; 14():265. PubMed ID: 27629831
[TBL] [Abstract][Full Text] [Related]
6. A framework to predict the applicability of Oncotype DX, MammaPrint, and E2F4 gene signatures for improving breast cancer prognostic prediction.
Yao K; Tong CY; Cheng C
Sci Rep; 2022 Feb; 12(1):2211. PubMed ID: 35140308
[TBL] [Abstract][Full Text] [Related]
7. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
8. Clinical and molecular aspects of breast cancer: Targets and therapies.
Godone RLN; Leitão GM; Araújo NB; Castelletti CHM; Lima-Filho JL; Martins DBG
Biomed Pharmacother; 2018 Oct; 106():14-34. PubMed ID: 29945114
[TBL] [Abstract][Full Text] [Related]
9. Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer.
Wu HJ; Chu PY
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435254
[TBL] [Abstract][Full Text] [Related]
10. Resistance to endocrine therapy in HR + and/or HER2 + breast cancer: the most promising predictive biomarkers.
Miranda F; Prazeres H; Mendes F; Martins D; Schmitt F
Mol Biol Rep; 2022 Jan; 49(1):717-733. PubMed ID: 34739691
[TBL] [Abstract][Full Text] [Related]
11. Predictive biomarkers for personalized medicine in breast cancer.
Rodrigues-Ferreira S; Nahmias C
Cancer Lett; 2022 Oct; 545():215828. PubMed ID: 35853538
[TBL] [Abstract][Full Text] [Related]
12. Identification of Personalized Chemoresistance Genes in Subtypes of Basal-Like Breast Cancer Based on Functional Differences Using Pathway Analysis.
Wu T; Wang X; Li J; Song X; Wang Y; Wang Y; Zhang L; Li Z; Tian J
PLoS One; 2015; 10(6):e0131183. PubMed ID: 26126114
[TBL] [Abstract][Full Text] [Related]
13. Drug Metabolism for the Identification of Clinical Biomarkers in Breast Cancer.
Costa B; Vale N
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328602
[TBL] [Abstract][Full Text] [Related]
14. Genetic heterogeneity in breast cancer: the road to personalized medicine?
Baird RD; Caldas C
BMC Med; 2013 Jun; 11():151. PubMed ID: 23800221
[TBL] [Abstract][Full Text] [Related]
15. Signatures of tumor-immune interactions as biomarkers for breast cancer prognosis.
Manjili MH; Najarian K; Wang XY
Future Oncol; 2012 Jun; 8(6):703-11. PubMed ID: 22764768
[TBL] [Abstract][Full Text] [Related]
16. Molecular Genomic Testing for Breast Cancer: Utility for Surgeons.
Fayanju OM; Park KU; Lucci A
Ann Surg Oncol; 2018 Feb; 25(2):512-519. PubMed ID: 29159748
[TBL] [Abstract][Full Text] [Related]
17. Transcriptomic Analysis of Breast Cancer Patients Sensitive and Resistant to Chemotherapy: Looking for Overall Survival and Drug Resistance Biomarkers.
Barrón-Gallardo CA; Garcia-Chagollán M; Morán-Mendoza AJ; Delgadillo-Cristerna R; Martínez-Silva MG; Aguilar-Lemarroy A; Jave-Suárez LF
Technol Cancer Res Treat; 2022; 21():15330338211068965. PubMed ID: 34981997
[TBL] [Abstract][Full Text] [Related]
18. Molecular profiling: an essential technology enabling personalized medicine in breast cancer.
Liu J; Li S; Dunker AK; Uversky VN
Curr Drug Targets; 2012 Apr; 13(4):541-54. PubMed ID: 22250651
[TBL] [Abstract][Full Text] [Related]
19. Abnormal Long Non-Coding RNAs Expression Patterns Have the Potential Ability for Predicting Survival and Treatment Response in Breast Cancer.
Pavanelli AC; Mangone FR; Barros LRC; Machado-Rugolo J; Capelozzi VL; Nagai MA
Genes (Basel); 2021 Jun; 12(7):. PubMed ID: 34209776
[TBL] [Abstract][Full Text] [Related]
20. The emerging role of the molecular diagnostics laboratory in breast cancer personalized medicine.
De Abreu FB; Wells WA; Tsongalis GJ
Am J Pathol; 2013 Oct; 183(4):1075-1083. PubMed ID: 23920325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
